Latest news
Novadiscovery raises series A financing to scale its in silico clinical trial platform – Debiopharm leads the round with EUR…
Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada
Grand gagnant du Challenge 2019 pour la qualité de vie du patient, le projet Rise-Up de chaise élévatrice qui aide…
Après-demain Holding SA acquiert une participation dans le réseau de crèches Little Green House (Suisse)
Debiopharm progresses in their stand against drug-resistant N. gonorrhoeae with extended CARB-X funding of their Debio 1453 antibiotic program
A pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor (ICI)-resistant disease by…
Debiopharm’s novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients
The Japanese Cancer Association and Debiopharm Announce Winners of the 2019 JCA-Mauvernay Award
Debiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
Stay informed
Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.